Novel ADC Achieves Impressive PFS Advantage in HER2-Low Metastatic Breast Cancer
(MedPage Today) -- Patients with recurrent or metastatic HER2-low breast cancer had dramatic improvement in progression-free survival (PFS) when treated with a novel antibody-drug conjugate (ADC) targeting HER2, a large randomized trial showed...
A novel antibody-drug conjugate (ADC) targeting HER2, rolditamig deuderuxtecan (TQB2102), has demonstrated a significant improvement in progression-free survival (PFS) for patients with HER2-low metastatic breast cancer, according to a large randomized trial presented at the European Society for Medical Oncology (ESMO) congress in Madrid.
The trial showed that median PFS tripled from 5.5 months with chemotherapy to 16.4 months with TQB2102, and a preliminary analysis of overall survival (OS) indicated a more than 50% reduction in the hazard ratio for both hormone receptor-positive/HER2-low and overall HER2-low populations. The trial also highlighted a statistically significant and clinically meaningful improvement in PFS and a trend toward OS benefit versus chemotherapy in patients with HER2-low recurrent or metastatic breast cancer.
Brief written by urgent.news from MedPage Today's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
